Last reviewed · How we verify

NCT07442916

Non-Invasive Brain Stimulation as Add-on Treatment in Chronic Migraine With Medication Overuse

Completed NA Last updated 2 March 2026
What this trial tests

NA trial testing Active rTMS Motor Cortex Face in Chronic Migraine in 60 participants. Completed in 30 January 2026.

Timeline
2 January 2024
Primary endpoint
30 January 2026
30 January 2026

Quick facts

Lead sponsorIRCCS National Neurological Institute "C. Mondino" Foundation
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment60
Start date2 January 2024
Primary completion30 January 2026
Estimated completion30 January 2026
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

IRCCS National Neurological Institute "C. Mondino" Foundation

Who can join

Adults 18 to 80, any sex, with Chronic Migraine or Medication Overuse Headache. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized, double-blind, sham-controlled clinical trial aims to evaluate the efficacy of non-invasive brain stimulation as an add-on treatment to standard detoxification therapy in patients with chronic migraine and medication overuse. The study also seeks to identify sensory and biochemical biomarkers predictive of treatment response.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Chronic Migraine

Currently open trials in the same condition.

Other IRCCS National Neurological Institute "C. Mondino" Foundation trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07442916.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing